Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease

OBJECTIVE: To test the safety, tolerability, and pharmacokinetics of the anti- TNF-α monoclonal antibody, infliximab, in subjects with intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD). STUDY DESIGN: We conducted a multicenter, randomized, prospective trial of second IVIG infusion (2...

詳細記述

保存先:
書誌詳細
主要な著者: Burns, Jane C., Best, Brookie M., Mejias, Asuncion, Mahony, Lynn, Fixler, David E., Jafri, Hasan S., Melish, Marian E., Jackson, Mary Anne, Asmar, Basim I., Lang, David J., Connor, James D., Capparelli, Edmund V., Keen, Monica L., Mamun, Khalid, Keenan, Gregory F., Ramilo, Octavio
フォーマット: Artigo
言語:Inglês
出版事項: 2008
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2856847/
https://ncbi.nlm.nih.gov/pubmed/18672254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jpeds.2008.06.011
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料